Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2021 Earnings Conference Call March 3, 2022 8:00 AM ET Company Participants Christi Waarich - Director of Investor Relations Bryan Stuart - President and Chief Executive Officer Judy Dunn - President of R&D Esther Rajavelu - Chief Financial Officer Chris Morabito - Chief Medical Officer Conference Call Participants Dae Gon Ha - Stifel Joseph Schwartz - SVB Securities Matthew Harrison - Morgan Stanley Judah Frommer - Credit Suisse Ted Tenthoff - Piper Sandler Discl ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2021 Earnings Conference Call November 4, 2021 8:00 AM ET Company Representatives Bryan Stuart - President, Chief Executive Officer Chris Morabito - Chief Medical Officer Peter Thomson - Vice President of Finance & Accounting Judy Dunn - President of R&D Paul Bruno - Senior Director of Corporate Development Naomi Aoki - Senior Vice President of Corporate Communications, Investor Relations Conference Call Participants Dae Gon Ha - Stiefel Ted Tenthoff - Piper Sandl ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2021 Earnings Conference Call August 10, 2021 8:00 AM ET Company Participants Christi Waarich - Director, IR & Corporate Communications Bryan Stuart - President & CEO Chris Moxham - CSO Chris Morabito - CMO Conference Call Participants Ted Tenthoff - Piper Sandler Dae Gon Ha - Stiefel Joseph Schwartz - SVB Leerink Matthew Harrison - Morgan Stanley Tazeen Ahmad - Bank of America Judah Frommer - Credit Suisse Operator Good morning, and welcome to the Fulcrum Therape ...

Fulcrum | --- | --- | --- | --- | |-------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Regulating Gene Expression to Treat the Root Cause of Disease May 2021 | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development status of the Com ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q1 2021 Earnings Conference Call May 6, 2021 8:00 AM ET Company Participants Christi Waarich - Director, Investor Relations & Corporate Communications Bryan Stuart - President & Chief Executive Officer Chris Moxham - Chief Scientific Officer Peter Thomson - Vice President, Finance & Accounting Conference Call Participants Kelly Girskis - SVB Leerink Ted Tenthoff - Piper Sandler Kostas Biliouris - Morgan Stanley Tazeen Ahmad - Bank of America Operator Good morning, a ...

Fulcrum | --- | --- | --- | --- | --- | |---------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | Regulating Gene Expression to Treat the Root Cause of Disease March 2021 | | | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the dev ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2020 Results Earnings Conference Call March 4, 2021 8:00 AM ET Company Participants Christi Waarich - Director, Investor Relations and Corporate Communications Robert Gould - President & CEO Bryan Stuart - Chief Operating Officer Chris Moxham - Chief Scientific Officer Peter Thomson - Vice President, Finance and Accounting Conference Call Participants Ted Tenthoff - Piper Sandler Joseph Schwartz - SVB Leerink Dae Gon Ha - Stifel Matthew Harrison - Morgan Stanley O ...

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q3 2020 Earnings Conference Call November 9, 2020 8:00 AM ET Company Participants Robert Gould - CEO, President & Director Diego Cadavid - SVP of Clinical Development Owen Wallace - Chief Scientific Officer Bryan Stuart - Chief Operating Officer Christi Waarich - Director, Corporate Communications & IR Conference Call Participants Ted Tenthoff - Piper Sandler Joseph Schwartz - SVB Leerink Kostas Biliouris - Morgan Stanley Operator Good morning, and welcome to the Ful ...

Fulcrum | --- | --- | --- | --- | |-------------------------------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | Regulating Gene Expression to Treat the Root Cause of Disease September 2020 | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development statu ...

Fulcrum | --- | --- | --- | --- | --- | --- | |---------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Fulcrum Q2 2020 Conference Call | | | | | | | August 11, 2020 | | | | | | | | | | | | | | | | | | | | Disclaimer and Notice This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regard ...